World
AstraZeneca 2nd dose does not increase risk of blood clots, says study
A second dose of AstraZeneca’s Covid vaccine does not increase the instances of rare blood clots, according to a new study.
Data published in the Lancet medical journal on Wednesday found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the Vaxzevria vaccine, the official name of the vaccine, was 2.3 per million in those inoculated. This is comparable to the typical rate seen in those who have not been vaccinated. The rate after the first dose is 8.1 per million.
The AstraZeneca-led and funded study evaluated reported cases on the drugmaker’s global safety database occurring within 14 days of administration of the first or second dose as of April 30.
